Details of Metabolite

General Information of MET (ID: META00205)
Name myo-Inositol
Synonyms   Click to Show/Hide Synonyms of This Metabolite
(1R,2R,3S,4S,5R,6S)-Cyclohexane-1,2,3,4,5,6-hexol; 1,2,3,4,5,6-HEXAHYDROXY-cyclohexane; 1,2,3,5/4,6-cyclohexanehexol; 1D-Myo-inositol; 1l-Myo-inositol; Bios I; Cyclohexitol; D-Myo-inositol; Dambose; I-inositol; Inosital; Inosite; Inositol; Ins; Iso-inositol; L-Myo-inositol; MI; Meat sugar; Meso-inositol; Myo inositol; Myo-inositol; Myoinosite; Myoinositol; Phaseomannite; Rat antispectacled eye factor; Vitamin b8; cis-1,2,3,5-trans-4,6-Cyclohexanehexol
Source Endogenous;Escherichia Coli Metabolite;Yeast Metabolite;Food;Cosmetic;Food additives;Microbial
Structure Type   Alcohols and polyols  (Click to Show/Hide the Complete Structure Type Hierarchy)
Organic oxygen compounds
Organooxygen compounds
Alcohols and polyols
HMDB ID
HMDB0000211
Formula
C6H12O6
Structure
2D MOL
KEGG ID
C00137
DrugBank ID
DB13178
ChEBI ID
17268
FooDB ID
FDB010547
ChemSpider ID
10239179
METLIN ID
5221
Function
myo-Inositol is an inositol isoform. Inositol is a derivative of cyclohexane with six hydroxyl groups, making it a polyol. It also is known as a sugar alcohol, having exactly the same molecular formula as glucose or other hexoses. Inositol exists in nine possible stereoisomers, of which cis-1,2,3,5-trans-4,6-cyclohexanehexol, or myo-inositol is the most widely occurring form in nature. The other known inositols include scyllo-inositol, muco-inositol, D-chiro-inositol, L-chiro-inositol, neo-inositol, allo-inositol, epi-inositol and cis-inositol. myo-Inositol is found naturally in many foods (particularly in cereals with high bran content) and can be used as a sweetner as it has half the sweetness of sucrose (table sugar). myo-Inositol was once considered a member of the vitamin B complex and given the name: vitamin B8. However, because it is produced by the human body from glucose, it is not an essential nutrient, and therefore cannot be called a vitamin. myo-Inositol is a precursor molecule for a number of secondary messengers including various inositol phosphates. In addition, inositol/myo-inositol is an important component of the lipids known as phosphatidylinositol (PI) phosphatidylinositol phosphate (PIP). myo-Inositol is synthesized from glucose, via glucose-6-phosphate (G-6-P) in two steps. First, G-6-P is isomerised by an inositol-3-phosphate synthase enzyme to myo-inositol 1-phosphate, which is then dephosphorylated by an inositol monophosphatase enzyme to give free myo-inositol. In humans, myo-inositol is primarily synthesized in the kidneys at a rate of a few grams per day. myo-Inositol can be used in the management of preterm babies who have or are at a risk of infant respiratory distress syndrome. It is also used as a treatment for polycystic ovary syndrome (PCOS). It works by increasing insulin sensitivity, which helps to improve ovarian function and reduce hyperandrogenism. Reduced levels of myo-inositol have been found in the spinal fluid of depressed patients and levels are significantly reduced in brain samples of suicide victims.
Regulatory Network
Full List of Protein(s) Regulating This Metabolite
      Hydrolases (EC 3)
            Leukotriene-C4 hydrolase (GGT1) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Knockdown (siRNA) of GGT1
                      Induced Change myo-Inositol concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Renal cell carcinoma [ICD-11: 2C90]
                      Details It is reported that knockdown of GGT1 leads to the increase of myo-inositol levels compared with control group.
            Sulfatase sulf-1 (SULF1) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Knockdown (shRNA) of SULF1
                      Induced Change myo-Inositol concentration: increase (FC = 3.10 - 3.79)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Ovarian cancer [ICD-11: 2C73]
                      Details It is reported that knockdown of SULF1 leads to the increase of myo-inositol levels compared with control group.
      Lyases (EC 4)
            Selenocysteine lyase (SCLY) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [3]
                      Introduced Variation Knockout of Scly
                      Induced Change myo-Inositol concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that knockout of Scly leads to the increase of myo-inositol levels compared with control group.
      Pore-forming PNC peptide (PNC)
            Cellular tumor antigen p53 (TP53) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [4]
                      Introduced Variation Knockout of TP53
                      Induced Change myo-Inositol concentration: increase (Log2 FC=1.02)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Colon cancer [ICD-11: 2B90]
                      Details It is reported that knockout of TP53 leads to the increase of myo-inositol levels compared with control group.
      Sugar transporter (ST)
            Proton myo-inositol cotransporter (SLC2A13) Click to Show/Hide the Full List of Regulating Pair(s):   6 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair (1) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (LL22/23AA+YIRV599/602AIRA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 6)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (LL22/23AA+YIRV599/602AIRA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
               Regulating Pair (2) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (RRR4/6AAA +LL22/23AA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 6)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (RRR4/6AAA +LL22/23AA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
               Regulating Pair (3) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (RRR4/6AAA +LL22/23AA+YIRV599/602AIRA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 120)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (RRR4/6AAA +LL22/23AA+YIRV599/602AIRA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
               Regulating Pair (4) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (RRR4/6AAA+YIRV599/602AIRA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 6)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (RRR4/6AAA+YIRV599/602AIRA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
               Regulating Pair (5) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (YIRV599/602AIRA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 6)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (YIRV599/602AIRA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
               Regulating Pair (6) Experim Info click to show the details of experiment for validating this pair [5]
                      Introduced Variation Mutation (LL22/23AA) of Slc2a13
                      Induced Change myo-Inositol concentration: increase (FC = 6)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that mutation (LL22/23AA) of Slc2a13 leads to the increase of myo-inositol levels compared with control group.
      Zinc finger protein (ZIN)
            Protein snail homolog 1 (SNAI1) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [6]
                      Introduced Variation Knockdown (shRNA) of SNAI1
                      Induced Change myo-Inositol concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Breast cancer [ICD-11: 2C60]
                      Details It is reported that knockdown of Snai1 leads to the increase of myo-inositol levels compared with control group.
References
1 Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282.
2 Erratum to: Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer Metab. 2014 Nov 4;2:24.
3 Combined Omics Reveals That Disruption of the Selenocysteine Lyase Gene Affects Amino Acid Pathways in Mice. Nutrients. 2019 Oct 26;11(11):2584.
4 Integrative omics analysis of p53-dependent regulation of metabolism. FEBS Lett. 2018 Feb;592(3):380-393.
5 Identification of a mammalian H(+)-myo-inositol symporter expressed predominantly in the brain. EMBO J. 2001 Aug 15;20(16):4467-77.
6 Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nat Commun. 2017 Feb 8;8:14374.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.